Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
about
Mitochondrial apoptosis and BH3 mimeticsThe biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemiaChallenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological MalignancyManagement of elderly and unfit patients with chronic lymphocytic leukemia.The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Reappraising the timing of transplant for indolent non-Hodgkin lymphomas.Richter transformation of CLL.Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyAn extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractorinessLong-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation.How to unleash mitochondrial apoptotic blockades to kill cancers?New Pharmacotherapies in Chronic Lymphocytic Leukemia.hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents.MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 acetylationDevelopment of venetoclax for therapy of lymphoid malignancies.Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.Clinical Impact of the 2016 Update to the WHO Lymphoma Classification.Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.Venetoclax for the treatment of patients with chronic lymphocytic leukemia.Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future.Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia.The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Venetoclax: First Global Approval.Survival control of malignant lymphocytes by anti-apoptotic MCL-1.Magic pills: new oral drugs to treat chronic lymphocytic leukemia.Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell MalignanciesPredictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia.Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease.Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).Current Treatment of Chronic Lymphocytic Leukemia.
P2860
Q28069552-EA2B7626-879A-44CB-A65D-FFBF8D8530C2Q28075683-28533B14-3BE0-48B5-B069-75C0218E9461Q28080304-EAB6FE8F-5E7C-482D-AE09-97551B43D9F3Q30243914-687B3D6A-DC2C-492F-A379-C42C776DE75DQ30243968-2E50963C-B150-4067-B233-9492F3C11BC3Q30248407-4921D306-EE04-4427-B895-224B1AB22D41Q30249283-73110FF4-BC76-4BB8-919E-C635AA27B53AQ30252869-8CC85631-78A7-46B3-881A-E2448EEC2118Q33438428-38E9A326-DBA6-403F-9FA2-D2B99EF46CA0Q33709543-A8B372F8-2344-4B69-A0F2-DB656E7F6B42Q36219840-2BCF6293-BA06-4F68-ADD4-489846A8F570Q37587294-33C9268E-0092-4567-ACB5-48CA348FF033Q37605306-CA4F1170-0739-4891-B4EA-0B4B96B88C8DQ37657934-AFE57108-F8B6-4530-8DC3-0955DA31BE36Q37676956-71ECE4DA-47FE-421B-938F-BAFB4CC9F429Q37702281-502272A0-4C0B-492C-89F2-D4694A4D601CQ38646074-F899E176-9F25-49AD-89B2-C04E028557F1Q38663689-765F0872-7687-4FC6-B96A-7FC0AF5638B4Q38665207-0569156B-5699-4007-B13A-2A66062636E1Q38676574-0BDDFDAE-A3A2-4350-BC77-DE4FF1B4E8D6Q38685006-1E0A679C-9992-4801-AAB0-1AE9904FE21FQ38685358-294C6E85-5283-4B05-B1A0-37D27F9EF4E6Q38691282-A88B0753-8151-4CBA-8718-77C17C097090Q38722012-76711935-5184-428B-9B89-F324037C715AQ38738661-E6B71F5F-E263-499D-96BD-BDC403E1EC3AQ38744632-A61E7E6E-8898-433E-9BD9-F2149F0D1662Q38766548-91EBE0C3-EDCD-41DB-B399-7F6619B2E8F8Q38818283-2FE6619E-C8E8-41B5-9B2F-49DDB5949501Q38853500-A101BAB3-0E71-443C-A37B-0953F7F92D50Q38914858-0CA0674A-38A1-4B87-B5FF-2FA67A0F1220Q38943877-DF0A0083-F96A-478A-A215-AA6540042743Q38962267-D4F55D2B-73A9-49BD-9E71-744E7C00E91CQ38996888-07865AC9-0B43-4BAF-B5B2-3D8E16E198FAQ38997367-E04BE140-3EFD-464F-A4F9-48F792D09F38Q39006397-17900DC4-2FD5-4DCC-AE36-8544829B48BEQ39034465-9D53AFF9-1E72-4D85-8FE2-607ABAD91FD1Q39038037-2AD5E5D7-DE48-4ECF-B87E-2809E7F48576Q39040977-8F43A11A-C93F-4F6C-A208-77A24ADA4B74Q39065374-17AC92DB-414A-45C4-92A7-49DC8F901416Q39129372-65A068FF-8750-41C9-BFC8-4D6D66F673EC
P2860
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
description
2016 nî lūn-bûn
@nan
2016 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Venetoclax in relapsed or refr ...... re, open-label, phase 2 study.
@ast
Venetoclax in relapsed or refr ...... re, open-label, phase 2 study.
@en
type
label
Venetoclax in relapsed or refr ...... re, open-label, phase 2 study.
@ast
Venetoclax in relapsed or refr ...... re, open-label, phase 2 study.
@en
prefLabel
Venetoclax in relapsed or refr ...... re, open-label, phase 2 study.
@ast
Venetoclax in relapsed or refr ...... re, open-label, phase 2 study.
@en
P2093
P50
P921
P1433
P1476
Venetoclax in relapsed or refr ...... re, open-label, phase 2 study.
@en
P2093
Brenda Chyla
Elisa Cerri
Gary Gordon
Johannes Schetelig
John F Seymour
Maria Verdugo
Mehrdad Mobasher
Monali Desai
Rod Humerickhouse
P304
P356
10.1016/S1470-2045(16)30019-5
P50
P577
2016-05-10T00:00:00Z